The story of ALK itself is one of the great sagas of precision oncology. First identified in 1994 as part of an NPM-ALK fusion in non-Hodgkin lymphoma, the gene later achieved fame when the EML4-ALK fusion was discovered in non-small-cell lung cancer in 2007, opening the door to a series of remarkably effective ALK inhibitors such as crizotinib and its successors. ALK can be activated in cancer through several distinct mechanisms: gene fusions that create constitutively active chimeric kinases, activating point mutations, copy-number gains and amplifications, and abnormal transcriptional regulation. Each of these mechanisms is now routinely tested for in clinical laboratories, and each carries a different therapeutic implication. The question raised by ALK ATI is whether this alternative transcript represents a fifth, previously underappreciated route to ALK-driven malignancy, or whether it is a biological curiosity that has been overinterpreted by clinicians hungry for new actionable targets.

The original discovery, reported by Wiesner and colleagues in Nature in 2015, was striking. The researchers found that a subset of melanomas expressed ALK protein without any detectable gene fusion, and traced this expression to an alternative promoter within intron 19. In experimental models, the truncated protein appeared to be phosphorylated, to activate oncogenic signalling pathways, to drive tumour formation, and, tantalisingly, to confer sensitivity to crizotinib. Because the kinase domain remained intact and the inhibitory drugs target that domain, the logic seemed sound: a tumour dependent on ALK ATI signalling might respond to ALK inhibitors even without a fusion. This raised the prospect of a tumour-agnostic biomarker, one that could extend ALK-directed therapy to patients with melanoma, sarcoma and other solid tumours whose cancers lacked canonical ALK rearrangements.

Subsequent laboratory work added layers of intrigue. One study showed that the ALK ATI isoform, in a kinase-activity-dependent manner, induces structural changes in chromatin within the nucleus, suggesting the truncated protein might remodel gene expression programs directly rather than simply relaying signals at the cell surface. Another report found that ALK ATI interacts with the c-Myc oncogene and promotes cancer stem-cell-like properties in sarcoma models, hinting at a role in tumour initiation, metastasis and treatment resistance. More recently, a 2025 study in ovarian high-grade serous carcinoma described a transcriptional variant of ALK that appeared to promote apoptosis, an unexpected and paradoxical finding that complicates any simple story of ALK ATI as a straightforward oncogene. Together, these results painted a picture of a versatile and context-dependent molecule whose effects vary dramatically depending on tumour type and cellular environment.

But the edifice began to crack under the weight of independent replication attempts. As the Spanish review documents in detail, subsequent experiments did not consistently reproduce the original claims of growth-factor-independent transformation or sensitivity to ALK inhibitors. A 2021 study using genomic and experimental evidence concluded that ALK ATI does not predict single-agent sensitivity to ALK inhibitors. In melanoma models expressing the alternative transcript, researchers generally observed low levels of ALK phosphorylation and no selective drug response, undermining the central premise that ALK ATI marks tumours that will benefit from ALK-directed therapy. The discrepancy between the initial excitement and the follow-up data illustrates a familiar pattern in translational cancer research: early findings from a limited set of models can generate hypotheses that broader and more rigorous testing fails to confirm.

The clinical literature on ALK ATI is equally fragmented. Studies across melanoma, sarcoma, ovarian carcinoma and histiocytic neoplasms have been retrospective, have employed heterogeneous assays, and have reported inconsistent prevalence figures and contradictory prognostic associations. In melanoma, where the phenomenon was first described, surveys of primary and metastatic cutaneous tumours confirmed that ALK expression through alternative transcriptional initiation occurs, but its correlation with outcomes has been disputed. In histiocytic neoplasms, a 2026 study reported that ALK ATI drives nuclear ALK expression even in the absence of ALK fusions, adding another layer of complexity to the interpretation of ALK staining in these rare tumours. Meanwhile, isolated case reports, such as a PRKCA-fused blue melanocytoma expressing a truncated ALK isoform, demonstrate that the biology of truncated ALK expression can intersect with other genetic events in unpredictable ways.

Perhaps the most consequential part of the review concerns diagnostics. Standard clinical tests for ALK are simply not designed to detect ALK ATI, and misreading them can lead to dangerous conclusions. ALK immunohistochemistry, which detects the protein regardless of how it is produced, cannot distinguish between expression driven by a fusion, by amplification, by ATI or by aberrant expression in inflammatory conditions such as malakoplakia. Break-apart fluorescence in situ hybridization, which detects physical disruption of the ALK locus, will be negative in ALK ATI because the gene is not rearranged. Confirmation that a tumour expresses ALK ATI requires an RNA-based assay specifically designed to demonstrate transcription initiating from intron 19 and continuing into ALK exons 20 through 29, together with the exclusion of a canonical ALK fusion. Without this molecular rigour, a positive ALK stain in a fusion-negative tumour tells the clinician almost nothing actionable.

The authors’ bottom line is deliberately cautious and carries immediate practical weight for oncologists and pathologists. Current evidence, they conclude, supports ALK ATI as a context-dependent biological phenomenon rather than a validated tumour-agnostic driver or predictive biomarker. In plain terms, finding the transcript in a tumour does not establish that the tumour depends on it, and it certainly does not establish that the patient will benefit from an ALK inhibitor. Accordingly, the review states that ALK-inhibitor treatment should not be selected solely on the basis of ALK ATI outside a clinical trial or a carefully documented individual assessment. This is a direct challenge to any practice of treating ALK-immunopositive, fusion-negative tumours with expensive and toxic targeted drugs on the assumption that the alternative transcript is driving them.

The broader lesson extends beyond a single transcript. Pan-cancer transcriptome analyses have revealed that regulation through alternative promoters is pervasive across the human genome, meaning that many cancer genes likely have truncated or altered isoforms awaiting discovery. Distinguishing passenger transcription from true oncogenic dependence will require the same combination of rigorous functional validation, standardised RNA-based diagnostics and prospective clinical trials that ultimately separated genuine ALK fusions from lookalike findings. For now, ALK ATI stands as a cautionary tale and an open scientific question: a kinase fragment that once promised to widen the reach of precision oncology, and that may yet prove important in specific tumour contexts, but that today remains, in the measured words of the Alicante team, unproven as a basis for treatment decisions.

Subject of Research: The role of the ALK ATI alternative transcript as a potential driver and biomarker in solid tumours

Article Title: ALK ATI in solid tumours: biological evidence, diagnostic challenges, and clinical relevance. a narrative review

Article References: Borregón, M., Algarra, M.-A., & Benítez-Fuentes, J.-D. (2026). ALK ATI in solid tumours: biological evidence, diagnostic challenges, and clinical relevance, a narrative review. Molecular Biology Reports, 53(1), Article 1657. https://doi.org/10.1007/s11033-026-12833-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12833-4

Keywords: ALK, ALK ATI, alternative transcription initiation, solid tumours, melanoma, sarcoma, ALK inhibitors, crizotinib, molecular diagnostics, precision oncology, biomarkers, kinase signalling

To appreciate why this case matters, it helps to understand the biology. Anaplastic lymphoma kinase (ALK) rearrangements occur in roughly three to five percent of non-small cell lung cancers (NSCLC), most commonly in younger, never-smoking patients with adenocarcinoma histology. The rearrangement fuses the ALK gene with a partner gene, producing a constitutively active signaling kinase that drives uncontrolled cell growth. Because the malignant cell becomes addicted to this single aberrant signal, ALK inhibitors—starting with crizotinib and progressing through second- and third-generation agents such as alectinib, brigatinib, and lorlatinib—can produce dramatic and durable responses. Sequential use of these next-generation inhibitors has pushed median survival for ALK-positive metastatic disease into territory once unimaginable for stage IV lung cancer.

Yet resistance is inevitable. Tumors evolve under selective pressure, and the mechanisms they deploy fall into two broad categories. The first is on-target resistance: secondary mutations within the ALK kinase domain itself, such as the notorious G1202R substitution, which alters the drug-binding pocket and prevents inhibitors from latching on. The second is bypass signaling: the tumor rewires its circuitry, activating an entirely parallel pathway—often through amplification of MET or KIT, activation of RAS/MAPK, or transformation to small-cell histology—so that blocking ALK no longer matters. The third and rarest category is the acquisition of a bona fide driver mutation in a different gene, one that is itself clinically actionable. The present case falls squarely into this last, uncommon group.

The patient’s treatment course, as documented by Junyue Deng, Juan Li, and colleagues at the Cancer Center of Daping Hospital, Army Medical University, in collaboration with the Geneseeq Research Institute, reads like a tour of modern ALK therapeutics. She received crizotinib, the first-generation inhibitor, followed by alectinib, lorlatinib, and brigatinib in sequence, achieving exceptionally durable disease control for nearly nine years. Each drug in that lineup was deployed to overcome or forestall resistance to its predecessor, a strategy that has become standard practice in ALK-positive disease and that the case demonstrates can buy years of high-quality life.

The turning point came when the disease progressed despite multiple ALK inhibitors. Rather than simply switching to another ALK drug and hoping for the best, the clinical team performed next-generation sequencing (NGS) on cell sediment from a pericardial effusion—the fluid that had accumulated in the sac surrounding the heart. This is a technically meaningful choice. Pericardial effusion in advanced cancer often contains malignant cells, and its cell sediment can yield DNA of sufficient quality for targeted sequencing. When tissue biopsy is difficult, risky, or infeasible—particularly when the relevant disease site is deep in the chest or the patient is frail—effusion-based molecular profiling offers a minimally invasive window into the tumor’s current genotype.

The sequencing result was striking: an EGFR L858R mutation with a variant allele frequency (VAF) of 12.05 percent. L858R is one of the two classic sensitizing EGFR mutations in lung adenocarcinoma, substituting a leucine at position 858 of the EGFR kinase domain with an arginine. The substitution destabilizes the inactive conformation of the kinase, locking the receptor into its active state and rendering it exquisitely sensitive to EGFR tyrosine kinase inhibitors. Crucially, the team also performed retrospective NGS on the patient’s archival baseline lymph node specimen—the tissue obtained at diagnosis before any therapy—using the same DNA-based targeted panel. That original sample contained neither the EGFR L858R mutation nor, notably, a detectable ALK fusion. The comparison strongly suggests that the EGFR mutation was acquired during treatment, a genuine instance of clonal evolution under drug pressure rather than a co-existing alteration missed at baseline.

The clinical response to this molecular detective work was immediate and gratifying. Treatment was switched to osimertinib, the third-generation EGFR inhibitor designed to selectively target sensitizing EGFR mutations while sparing wild-type EGFR, thereby limiting the skin and gastrointestinal toxicity that plagued earlier EGFR drugs. Under RECIST 1.1 criteria—the international standard for measuring tumor burden on imaging—the patient achieved a partial response, meaning a substantial shrinkage of measurable lesions. This was accompanied by a marked decline in serum carcinoembryonic antigen (CEA), a tumor marker whose falling levels served as an independent biochemical confirmation that the EGFR-driven clone was being brought under control. Disease control has been maintained through month 107 of her overall treatment course.

The implications of this single case ripple outward in several directions. First, it reinforces a principle that oncologists repeat like a mantra but that is still unevenly applied in practice: re-biopsy at progression matters. When a tumor stops responding to a targeted therapy, the resistance mechanism cannot be reliably guessed. Secondary ALK mutations, bypass activation, phenotypic transformation, and—as here—an entirely new druggable driver can all be at play, and each demands a different therapeutic answer. Treating progression blindly risks burning months on a drug the tumor has already outmaneuvered. Repeat molecular profiling, whether from tissue, blood plasma, or effusion specimens, converts a guessing game into a rational prescription.

Second, the case highlights the value of cytology-based and effusion-based sequencing as a complement to tissue biopsy. Pericardial effusions are clinically significant events in advanced NSCLC, and their malignant cell sediment is often discarded after cytological diagnosis. The demonstration that this material can yield an actionable result—here, a mutation at a VAF above 12 percent, well within the detection range of standard targeted panels—argues for routine molecular profiling of such specimens whenever conventional sampling is impractical. It also underscores why paired analysis of archival baseline tissue and progression-time samples is so informative: without the retrospective sequencing of the original lymph node, the acquired nature of the EGFR mutation would have remained uncertain, and the possibility of a baseline co-mutation misclassified as primary ALK-driven disease could not have been excluded.

Finally, the report is a vivid illustration of how far sequential targeted therapy has come. A patient diagnosed with stage IV ALK-positive lung cancer once faced a prognosis measured in months; this woman has lived through four generations of ALK inhibitors and then pivoted to a fifth targeted drug against a different kinase, remaining in ongoing disease control nearly nine years on. Resistance, in this framing, is not a wall but a series of doors—each opened by understanding the tumor’s latest move. The case, published open access with the support of the Science-Health Joint Medical Scientific Research Project of Chongqing, adds to the growing evidence that vigilant, repeated genomic surveillance can keep patients with driver-mutant lung cancer one step ahead of their disease. For clinicians, the message is clear: when ALK-targeted therapy fails after years of success, look again at the tumor’s genome, because the answer may be another approved drug waiting in the wings.

Subject of Research: Acquired EGFR L858R mutation as a resistance mechanism to sequential ALK inhibitor therapy in ALK-rearranged non-small cell lung cancer

Article Title: Detection of an EGFR L858R mutation following prolonged sequential ALK-TKI therapy in ALK-rearranged NSCLC: a case report

Article References: Detection of an EGFR L858R mutation following prolonged sequential ALK-TKI therapy in ALK-rearranged NSCLC: a case report. (n.d.). https://doi.org/10.1007/s00432-026-06604-8

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06604-8

Keywords: ALK-rearranged NSCLC, EGFR L858R, acquired resistance, ALK inhibitors, osimertinib, next-generation sequencing, pericardial effusion, liquid biopsy, targeted therapy, lung cancer, case report, tumor evolution